• Glenn Hearson

More positive results from #ANDHI study for Benralizumab in Severe Eosinophilic Asthma

The #ANDHI study, has recently had more results published in the European Journal of Allergy and Clinical Immunology "Benralizumab Improves Symptoms of Patients with Severe, Eosinophilic Asthma with a Diagnosis of Nasal Polyposis"


Professor Tim Harrison was our local principal investigator for this study, which was managed by Liz Dark and the Asthma team.


The study investigated whether Benralizumab could help to decrease asthma flare-ups, improve lung health and also improve quality of life.


The published findings showed that data from #ANDHI demonstrated the efficacy profile of benralizumab for patients with severe, eosinophilic asthma and NP, with improvement in SNOT-22 questionnaire and asthma outcomes.